Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor.

ABSTRACT:

Background

Single-agent amrubicin chemotherapy is a key regimen, especially for small cell lung cancer (SCLC); however, it can cause severe myelosuppression.

Purpose

The purpose of this study was to determine the real-world incidence of febrile neutropenia (FN) among patients treated with single-agent amrubicin chemotherapy for thoracic malignancies.

Patients and methods

The medical records of consecutive patients with thoracic malignancies, including SCLC and non-small cell lung cancer (NSCLC), who were treated with single-agent amrubicin chemotherapy in cycle 1 between January 2010 and March 2020, were retrospectively analyzed.

Results

One hundred and fifty-six patients from four institutions were enrolled. Their characteristics were as follows: median age (r

SUBMITTER: Dotsu Y 

PROVIDER: S-EPMC8464789 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature